Guangdong Feinan Resources Recycling (301500.SZ) won the bid for a destruction-type scrap disposal project for a communications equipment enterprise.
Feinan Resources (301500.SZ) announced that the company recently received a "Letter of Acceptance" from the tendering party (a well-known domestic enterprise engaged in communications equipment). The company won the bid for the tendering party's destruction-type scrap disposal project. The project term is from October 2026 to September 2028. The scrap mainly includes waste circuit boards, waste cabinet subracks, waste electronic components (including chips, optical modules, etc.), waste modules, waste lithium batteries, waste energy storage systems, waste materials, etc. The estimated quantity of scrap awarded under the project term is approximately 21,000 tons.
Guangdong Feinan Resources Recycling (301500.SZ) announced that the company recently received a "Notice of Award" from the tendering party (a well-known domestic enterprise engaged in communications equipment), confirming that the company has won the bid for the tendering party's destruction-type scrap disposal project. The project term runs from October 2026 to September 2028. The scrap materials mainly include waste circuit boards, waste cabinet subracks, waste electronic components (including chips, optical modules, etc.), waste modules, waste lithium batteries, waste energy storage systems, waste documents, etc. The volume of awarded scrap materials during the project term is estimated at approximately 21,000 tons.
The company is primarily engaged in the disposal of non-ferrous metal hazardous waste and the recycling and utilization of renewable resources. The awarded project falls within the company's ordinary business scope and can expand the company's sources of raw material procurement for renewable resources. The specific quantities of scrap materials collected and transported and the procurement amounts paid by the company shall be subject to actual collection and transportation. If the awarded project is implemented smoothly, it is expected to have a positive impact on the company's overall operations, will not affect the independence of the company's business, and will not have a material impact on the company's operating performance in the short term.
Related Articles

Nanjing King-Friend Biochemical Pharmaceutical (603707.SH) subsidiary obtains US FDA registration approval for additional manufacturing site for amikacin sulfate injection

Jinling Pharmaceutical (000919.SZ) subsidiary's arotinolol hydrochloride API approved for marketing.

Morgan Stanley: HSBC HOLDINGS (00005) and STANCHART (02888) valuations are more attractive than their Singapore peers.
Nanjing King-Friend Biochemical Pharmaceutical (603707.SH) subsidiary obtains US FDA registration approval for additional manufacturing site for amikacin sulfate injection

Jinling Pharmaceutical (000919.SZ) subsidiary's arotinolol hydrochloride API approved for marketing.

Morgan Stanley: HSBC HOLDINGS (00005) and STANCHART (02888) valuations are more attractive than their Singapore peers.






